Evaluate’s 2026 Orphan Drugs Report forecasts global orphan drug sales will exceed $400 billion by 2032, estimating $409 billion annually and a rising share of total prescription revenue. The lead sentence: analysts attribute growth to new launches, label expansions, and continued premium pricing despite regulatory scrutiny and policy headwinds. The report flags FDA volatility and pricing pressures as risks, while naming established franchises and next‑gen gene and cell therapies as revenue drivers; it calls out J&J and Vertex among firms with multiple top‑selling orphan products.